Stock Market LIVE Updates | Zydus Lifesciences gets final USFDA approval for Celecoxib capsules
The company has received final approval from the US Food and Drug Administration (USFDA) for its Celecoxib capsules, which will be available in 50 mg, 100 mg, 200 mg, and 400 mg strengths.
Celecoxib is used to treat pain and inflammation caused by various conditions such as arthritis, ankylosing spondylitis, and menstrual pain.
Zydus Lifesciences was quoting at Rs 968.40, up Rs 1.25, or 0.13 percent.
It has touched an intraday high of Rs 982.95 and an intraday low of Rs 966.40.
It was trading with volumes of 19,920 shares, compared to its five day average of 48,841 shares, a decrease of -59.21 percent.
In the previous trading session, the share closed down 0.14 percent or Rs 1.35 at Rs 967.15.
The share touched a 52-week high of Rs 1,323.90 and a 52-week low of Rs 797.05 on 09 August, 2024 and 07 April, 2025, respectively.
Currently, the stock is trading 26.85 percent below its 52-week high and 21.5 percent above its 52-week low.
Market capitalisation stands at Rs 97,443.70 crore.